Sponsors / ALMS
ALMS

Alumis Inc

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
7Trials in this database
14Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque PsoriasisNCT05600036ALMSPhase 2Completed2023-06-29Actual
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisNCT05739435ALMSPhase 2Active not recruiting2027-12-01Estimated
POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUNCT05953688ALMSPhase 2Terminated2024-08-13Actual
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusNCT05966480ALMSPhase 2Active not recruiting2026-06-23Actual
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisNCT06586112ALMSPhase 3Completed2025-09-19Actual
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001NCT06588738ALMSPhase 3Completed2025-09-23Actual
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque PsoriasisNCT06846541ALMSPhase 3Active not recruiting2028-11Estimated

Latest recorded trial changes